EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
LOADING
|||
Switch Symbol:
Revenue Growth Under Pressure
Below historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
-81.89%
↓ 209% below average
Average (39q)
75.33%
Historical baseline
Range
High:2055.60%
Low:-90.12%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -81.89% |
| Q2 2025 | -78.19% |
| Q1 2025 | 111.02% |
| Q4 2024 | 10.11% |
| Q3 2024 | 11.05% |
| Q2 2024 | -18.89% |
| Q1 2024 | -16.71% |
| Q4 2023 | -7.72% |
| Q3 2023 | 66.96% |
| Q2 2023 | 18.51% |
| Q1 2023 | -27.06% |
| Q4 2022 | 5.20% |
| Q3 2022 | -13.43% |
| Q2 2022 | 24.44% |
| Q1 2022 | -19.49% |
| Q4 2021 | 27.43% |
| Q3 2021 | 0.51% |
| Q2 2021 | 23.08% |
| Q1 2021 | 2.69% |
| Q4 2020 | -54.57% |
| Q3 2020 | 280.76% |
| Q2 2020 | -44.96% |
| Q1 2020 | -13.25% |
| Q4 2019 | 244.08% |
| Q3 2019 | -65.20% |
| Q2 2019 | 258.35% |
| Q1 2019 | -17.61% |
| Q4 2018 | 402.47% |
| Q3 2018 | -32.03% |
| Q2 2018 | -22.95% |
| Q1 2018 | -0.54% |
| Q4 2017 | 142.34% |
| Q3 2017 | -45.08% |
| Q2 2017 | 18.81% |
| Q1 2017 | -90.12% |
| Q4 2016 | 2055.60% |
| Q3 2016 | -8.88% |
| Q2 2016 | -6.17% |
| Q1 2016 | -38.40% |
| Q4 2015 | 12.88% |